AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 22218164 — intervention group
Group type: EXPERIMENTAL
Intervention: Adaptive regulation strategies (accept, reappraise)
Number of subjects: 0
Study 22218164 — intervention group
Group type: COMPARATOR
Intervention: No specific regulation instructions
Number of subjects: 0
Study 20022869 — intervention group
Group type: EXPERIMENTAL
Intervention: 2DTEE planimetry method
Number of subjects: 70
Study 20022869 — intervention group
Group type: EXPERIMENTAL
Intervention: 3DTEE method
Number of subjects: 70
Study 20022869 — intervention group
Group type: EXPERIMENTAL
Intervention: 2DTEE short-axis images during systole
Number of subjects: 70
Study 20022869 — intervention group
Group type: EXPERIMENTAL
Intervention: 2DTEE and 3DTEE methods
Number of subjects: 70
Study 17666600 — intervention group
Group type: EXPERIMENTAL
Intervention: IV ferric carboxymaltose (less than or equal to 1,000 mg over 15 minutes, repeated weekly to achieve a total calculated replacement dose)
Number of subjects: 352
Study 17666600 — intervention group
Group type: COMPARATOR
Intervention: Oral iron (ferrous sulfate 325 mg orally thrice daily for 6 weeks)
Number of subjects: 352
Study 16110231 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral amino acids (12 g/day)
Number of subjects: 100
Study 12177099 — intervention group
Group type: EXPERIMENTAL
Intervention: Fulvestrant 250 mg once-monthly intramuscular injection
Number of subjects: 451
Study 12177099 — intervention group
Group type: COMPARATOR
Intervention: Anastrozole 1 mg oral dose
Number of subjects: 451
Study 9870019 — intervention group
Group type: EXPERIMENTAL
Intervention: Internal transcatheter cardioversion
Number of subjects: 40
Study 9870019 — intervention group
Group type: COMPARATOR
Intervention: External cardioversion
Number of subjects: 40
Study 9870019 — intervention group
Group type: EXPERIMENTAL
Intervention: Cross-over to internal cardioversion
Number of subjects: 40
Study 9870019 — intervention group
Group type: COMPARATOR
Intervention: Cross-over to external cardioversion
Number of subjects: 40
Study 9870019 — intervention group
Group type: EXPERIMENTAL
Intervention: Both methods
Number of subjects: 40
Study 9870019 — intervention group
Group type: COMPARATOR
Intervention: Internal vs External cardioversion
Number of subjects: 40
Study 7986410 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthy long-term HIV-positives (HLP)
Number of subjects: 588
Study 7986410 — intervention group
Group type: COMPARATOR
Intervention: Progressors (men with HIV seroconversion prior to 1983 but with AIDS or CD4+ counts < 200 x 10(6)/l)
Number of subjects: 588
Study 7986410 — intervention group
Group type: COMPARATOR
Intervention: HLP
Number of subjects: 588
Study 2686658 — intervention group
Group type: EXPERIMENTAL
Intervention: Tromantadine
Number of subjects: 120
Study 2686658 — intervention group
Group type: COMPARATOR
Intervention: Aciclovir
Number of subjects: 120
Study 31941523 — intervention group
Group type: EXPERIMENTAL
Intervention: Capecitabine plus Radium-223 (Xofigo™)
Number of subjects: 0
Study 31941523 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 28871621 — intervention group
Group type: EXPERIMENTAL
Intervention: Systolic blood pressure (SBP) decrease during the first 24 hours from randomization
Number of subjects: 1257
Study 28241780 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard coagulation tests-based transfusion strategy
Number of subjects: 0
Study 28241780 — intervention group
Group type: EXPERIMENTAL
Intervention: Thromboelastometry-based transfusion strategy
Number of subjects: 0
Study 28241780 — intervention group
Group type: EXPERIMENTAL
Intervention: Restrictive transfusion strategy
Number of subjects: 0
Study 25733000 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.8 mg pegfilgrastim
Number of subjects: 87
Study 25733000 — intervention group
Group type: EXPERIMENTAL
Intervention: 3.6 mg pegfilgrastim
Number of subjects: 87
Study 25733000 — intervention group
Group type: EXPERIMENTAL
Intervention: 6.0 mg pegfilgrastim
Number of subjects: 87
Study 23589326 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutrition-based shared medical appointment (SMA), three 90-minute sessions
Number of subjects: 94
Study 23589326 — intervention group
Group type: COMPARATOR
Intervention: Individualized counseling (control group)
Number of subjects: 94
Study 21534714 — intervention group
Group type: EXPERIMENTAL
Intervention: Botulinum toxin type A (BTX‐A) treatment followed by NeuroMuscular Retraining Therapy (NMRT)
Number of subjects: 20
Study 19331489 — intervention group
Group type: EXPERIMENTAL
Intervention: Topiramate (200 or 300 mg)
Number of subjects: 51
Study 19331489 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 51
Study 16677331 — intervention group
Group type: COMPARATOR
Intervention: 1100 ppmF, NaF (group A)
Number of subjects: 83
Study 16677331 — intervention group
Group type: EXPERIMENTAL
Intervention: 1100 ppmF, NaF and chlorhexidine 0.95% (group B)
Number of subjects: 83
Study 16677331 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorhexidine 0.95% (group C)
Number of subjects: 83
Study 15117007 — intervention group
Group type: EXPERIMENTAL
Intervention: Participants with strong protected values (PVs)
Number of subjects: 0
Study 15117007 — intervention group
Group type: COMPARATOR
Intervention: Participants with few protected values (PVs)
Number of subjects: 0
Study 11246614 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 MU IFN t.i.w. for 1 year (Group 1)
Number of subjects: 538
Study 11246614 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 MU IFN t.i.w. for 1 year (Group 2)
Number of subjects: 538
Study 11246614 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 MU IFN t.i.w. for 1 year (Group 3)
Number of subjects: 538
Study 11246614 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 MU IFN t.i.w. for 1 year (Group 4)
Number of subjects: 538
Study 11246614 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 MU IFN t.i.w. for 1 year (Group 5)
Number of subjects: 538
Study 11246614 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 MU IFN t.i.w. for 1 year (Group 6)
Number of subjects: 538
Study 11246614 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 MU IFN daily for 2 months followed by 5 MU t.i.w. for a further 10 months (Group 7)
Number of subjects: 538
Study 9307535 — intervention group
Group type: EXPERIMENTAL
Intervention: Extra-amniotic saline
Number of subjects: 121
Study 9307535 — intervention group
Group type: COMPARATOR
Intervention: Intra-amniotic prostaglandin
Number of subjects: 121
Study 8039154 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulsed high dose chemotherapy
Number of subjects: 0
Study 8039154 — intervention group
Group type: EXPERIMENTAL
Intervention: Dose intensity regimens
Number of subjects: 0
Study 8039154 — intervention group
Group type: EXPERIMENTAL
Intervention: Peripheral blood progenitor cells
Number of subjects: 0
Study 8039154 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetically engineered hematopoietic growth factors
Number of subjects: 0
Study 2553568 — intervention group
Group type: EXPERIMENTAL
Intervention: PK 11195 (10 mg IV)
Number of subjects: 10
Study 2553568 — intervention group
Group type: COMPARATOR
Intervention: PK 11195 (100 mg oral)
Number of subjects: 10
Study 2553568 — intervention group
Group type: COMPARATOR
Intervention: PK 11195 (200 mg oral)
Number of subjects: 10
Study 2553568 — intervention group
Group type: COMPARATOR
Intervention: PK 11195 (400 mg oral)
Number of subjects: 10
Study 2553568 — intervention group
Group type: COMPARATOR
Intervention: Placebo (oral)
Number of subjects: 10
Study 59855 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethamsylate treatment (Dicynene)
Number of subjects: 22
Study 59855 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study 31705384 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral, Academic, and Social Engagement (BASE) classroom management model training for teachers
Number of subjects: 2925
Study 30850441 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-week aerobic training program using recombinant exercise bicycles, 3 times per week
Number of subjects: 40
Study 30850441 — intervention group
Group type: COMPARATOR
Intervention: Control period (no aerobic training)
Number of subjects: 40
Study 28228578 — intervention group
Group type: EXPERIMENTAL
Intervention: GSK249320
Number of subjects: 134
Study 28228578 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 134
Study 24800582 — intervention group
Group type: EXPERIMENTAL
Intervention: Spironolactone 100 mg/d and Furosemide 40 mg/d, adjusted every four days to a maximum of 400 mg/d and 160 mg/d respectively
Number of subjects: 80
Study 24800582 — intervention group
Group type: COMPARATOR
Intervention: Spironolactone 100 mg/d and Furosemide 40 mg/d, adjusted every seven days to a maximum of 400 mg/d and 160 mg/d respectively
Number of subjects: 80
Study 24800582 — intervention group
Group type: EXPERIMENTAL
Intervention: Observation group
Number of subjects: 80
Study 24800582 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 80
Study 22673139 — intervention group
Group type: EXPERIMENTAL
Intervention: Hib-MenC-TT group
Number of subjects: 268
Study 22673139 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 268
Study 22673139 — intervention group
Group type: EXPERIMENTAL
Intervention: DTaP-IPV recipients
Number of subjects: 268
Study 22673139 — intervention group
Group type: COMPARATOR
Intervention: DTaP-IPV-Hib recipients
Number of subjects: 268
Study 20337633 — intervention group
Group type: EXPERIMENTAL
Intervention: DMARDs (10 patients with methotrexate and 10 with adalimumab)
Number of subjects: 25
Study 18568687 — intervention group
Group type: EXPERIMENTAL
Intervention: Aggressive antihypertensive combination treatment
Number of subjects: 10173
Study 16082639 — intervention group
Group type: EXPERIMENTAL
Intervention: Infliximab
Number of subjects: 31
Study 16082639 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31
Study 16082639 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-DVU STIR score
Number of subjects: 31
Study 16082639 — intervention group
Group type: EXPERIMENTAL
Intervention: Status score
Number of subjects: 31
Study 16082639 — intervention group
Group type: EXPERIMENTAL
Intervention: Change score
Number of subjects: 31
Study 12430666 — intervention group
Group type: EXPERIMENTAL
Intervention: WBC-reduced RBCs and platelets
Number of subjects: 2780
Study 12430666 — intervention group
Group type: COMPARATOR
Intervention: Unmodified blood components
Number of subjects: 2780
Study 10355233 — intervention group
Group type: EXPERIMENTAL
Intervention: Masked rhyming prime
Number of subjects: 0
Study 10355233 — intervention group
Group type: EXPERIMENTAL
Intervention: Rhyme priming effect
Number of subjects: 0
Study 10355233 — intervention group
Group type: EXPERIMENTAL
Intervention: Phonological (rhyme detection) task
Number of subjects: 0
Study 10355233 — intervention group
Group type: EXPERIMENTAL
Intervention: Phonological and semantic priming effects
Number of subjects: 0
Study 8541683 — intervention group
Group type: EXPERIMENTAL
Intervention: Thrombolytic therapy with recombinant tissue‐type plasminogen activator for up to 4 hours followed by angioplasty (n = 11)
Number of subjects: 20
Study 8541683 — intervention group
Group type: COMPARATOR
Intervention: Angioplasty alone (n = 9)
Number of subjects: 20
Study 8541683 — intervention group
Group type: EXPERIMENTAL
Intervention: Thrombolytic therapy (n = 4 with limb-threatening ischemia)
Number of subjects: 20
Study 8541683 — intervention group
Group type: EXPERIMENTAL
Intervention: Thrombolytic therapy
Number of subjects: 20
Study 2790862 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoride toothpastes (sodium fluoride and sodium monofluorophosphate with calcium glycerophosphate)
Number of subjects: 22
Study 2790862 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium monofluorophosphate containing toothpaste
Number of subjects: 22
Study 2790862 — intervention group
Group type: COMPARATOR
Intervention: Control toothpaste (fluoride-free)
Number of subjects: 22
Study 754991 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative pressure of -49.1 kPa (-0.5 kp/cm2)
Number of subjects: 167
Study 754991 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative pressure of -78.5 kPa (-0.8 kp/cm2)
Number of subjects: 167
Study 754991 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 167
Study 31271875 — intervention group
Group type: EXPERIMENTAL
Intervention: Cocoa extract (600 mg/d cocoa flavanols)
Number of subjects: 2262
Study 31271875 — intervention group
Group type: EXPERIMENTAL
Intervention: Multivitamin
Number of subjects: 2262
Study 31271875 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 2262
Study 28256915 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg dehydroepiandrosterone (DHEA)
Number of subjects: 6
Study 28256915 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study 26048317 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous infusion of tirofiban at 0.075μg/kg/min for 24h
Number of subjects: 104
Study 22717993 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual-processing instruction
Number of subjects: 0
Study 22717993 — intervention group
Group type: COMPARATOR
Intervention: Undirected instruction
Number of subjects: 0
Study 21714879 — intervention group
Group type: EXPERIMENTAL
Intervention: LigaSure™ dissection technique
Number of subjects: 102
Study 21714879 — intervention group
Group type: COMPARATOR
Intervention: Conventional dissection technique
Number of subjects: 102
Study 19267951 — intervention group
Group type: EXPERIMENTAL
Intervention: Mediterranean diet
Number of subjects: 774
Study 19267951 — intervention group
Group type: COMPARATOR
Intervention: Conventional low-fat diet (Control)
Number of subjects: 774
Study 19267951 — intervention group
Group type: EXPERIMENTAL
Intervention: Mediterranean diet in diabetic patients
Number of subjects: 774
Study 16634720 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 8
Study 16634720 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 14685863 — intervention group
Group type: EXPERIMENTAL
Intervention: DWN
Number of subjects: 8
Study 14685863 — intervention group
Group type: COMPARATOR
Intervention: FLA
Number of subjects: 8
Study 11762686 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise (3 30-minute classes per week for 23 weeks)
Number of subjects: 50
Study 11762686 — intervention group
Group type: COMPARATOR
Intervention: Control (no exercise intervention)
Number of subjects: 50
Study 9640081 — intervention group
Group type: EXPERIMENTAL
Intervention: Salmon calcitonin (CT) at a dose of 100 i.v./days s.c. for three days in patients with chronic moderate bronchial asthma
Number of subjects: 24
Study 9640081 — intervention group
Group type: COMPARATOR
Intervention: Placebo (psychological saline) in patients with mild bronchial asthma
Number of subjects: 24
Study 8330463 — intervention group
Group type: EXPERIMENTAL
Intervention: Transnasal butorphanol (2 mg on day 1, followed by 1, 2, and 4 mg every 6 hours on days 2-6, 7-11, and 12-16)
Number of subjects: 18
Study 8330463 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 3106095 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxytocin (OT)
Number of subjects: 35
Study 3106095 — intervention group
Group type: COMPARATOR
Intervention: TRH alone
Number of subjects: 35
Study 3106095 — intervention group
Group type: COMPARATOR
Intervention: Saline
Number of subjects: 35
Study 31479083 — intervention group
Group type: COMPARATOR
Intervention: Computerized Cognitive Training (CCT)
Number of subjects: 96
Study 31479083 — intervention group
Group type: COMPARATOR
Intervention: Tai Chi (TC)
Number of subjects: 96
Study 29945954 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous immunoglobulin (IVIg) - single infusion of 0.8 g/kg
Number of subjects: 206
Study 29945954 — intervention group
Group type: COMPARATOR
Intervention: Careful observation
Number of subjects: 206
Study 26894413 — intervention group
Group type: EXPERIMENTAL
Intervention: Palbociclib plus letrozole (letrozole 2.5 mg daily + palbociclib 125 mg once daily for 3 weeks followed by 1 week off)
Number of subjects: 0
Study 26894413 — intervention group
Group type: COMPARATOR
Intervention: Letrozole alone (2.5 mg daily)
Number of subjects: 0
Study 25886227 — intervention group
Group type: EXPERIMENTAL
Intervention: Ropivacaine with 8 mg dexamethasone (30 ml of 0.5% ropivacaine with 2 ml dexamethasone)
Number of subjects: 80
Study 25886227 — intervention group
Group type: COMPARATOR
Intervention: Ropivacaine alone (30 ml of 0.5% ropivacaine with 2 ml distilled water)
Number of subjects: 80
Study 25886227 — intervention group
Group type: EXPERIMENTAL
Intervention: Ropivacaine with 8 mg dexamethasone
Number of subjects: 80
Study 25886227 — intervention group
Group type: COMPARATOR
Intervention: Ropivacaine alone
Number of subjects: 80
Study 23234472 — intervention group
Group type: EXPERIMENTAL
Intervention: Pressure-monitoring group (guidelines-based management with intraparenchymal intracranial pressure monitoring)
Number of subjects: 324
Study 23234472 — intervention group
Group type: COMPARATOR
Intervention: Imaging-clinical examination group (treatment based on imaging and clinical examination)
Number of subjects: 324
Study 23234472 — intervention group
Group type: EXPERIMENTAL
Intervention: Pressure-monitoring group
Number of subjects: 324
Study 23234472 — intervention group
Group type: COMPARATOR
Intervention: Imaging-clinical examination group
Number of subjects: 324
Study 20688546 — intervention group
Group type: EXPERIMENTAL
Intervention: Noninvasive interactive neurostimulation device (InterX)
Number of subjects: 60
Study 20688546 — intervention group
Group type: COMPARATOR
Intervention: Sham device
Number of subjects: 60
Study 19011441 — intervention group
Group type: EXPERIMENTAL
Intervention: Buprenorphine (BUP)
Number of subjects: 59
Study 19011441 — intervention group
Group type: EXPERIMENTAL
Intervention: Methadone (MMP)
Number of subjects: 59
Study 19011441 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 59
Study 19011441 — intervention group
Group type: EXPERIMENTAL
Intervention: Perceived stress
Number of subjects: 59
Study 15810908 — intervention group
Group type: EXPERIMENTAL
Intervention: BDDrFVIII (ReFacto) reconstituted with 5 mL of sterile water
Number of subjects: 0
Study 15810908 — intervention group
Group type: EXPERIMENTAL
Intervention: BDDrFVIII (ReFacto) reconstituted with 4 mL sodium chloride 0.9% USP
Number of subjects: 0
Study 15810908 — intervention group
Group type: COMPARATOR
Intervention: Hemofil M (plasma-derived, full-length FVIII preparation)
Number of subjects: 0
Study 12860795 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with 1 or more typical lesions on MRI
Number of subjects: 388
Study 12860795 — intervention group
Group type: COMPARATOR
Intervention: Patients with no lesions on MRI
Number of subjects: 388
Study 10673175 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoking cessation
Number of subjects: 3926
Study 10673175 — intervention group
Group type: EXPERIMENTAL
Intervention: Sustained quitters
Number of subjects: 3926
Study 10673175 — intervention group
Group type: COMPARATOR
Intervention: Continuing smokers
Number of subjects: 3926
Study 8848333 — intervention group
Group type: EXPERIMENTAL
Intervention: ATP-MgCl2 (0.6 mumol/kg/min)
Number of subjects: 14
Study 8848333 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (placebo)
Number of subjects: 14
Study 1510256 — intervention group
Group type: EXPERIMENTAL
Intervention: Laryngeal mask airway (LMA)
Number of subjects: 41
Study 1510256 — intervention group
Group type: COMPARATOR
Intervention: Tracheal intubation
Number of subjects: 41
Study 6379574 — intervention group
Group type: EXPERIMENTAL
Intervention: Scrub A (chlorhexidine digluconate 40 mg/ml)
Number of subjects: 113
Study 6379574 — intervention group
Group type: COMPARATOR
Intervention: Scrub B (benzalkonium chloride 5 mg/ml)
Number of subjects: 113
Study 30715489 — intervention group
Group type: EXPERIMENTAL
Intervention: mHealth-mediated exercise program (walking with a pedometer plus engagement in planned exercise supported by a mobile health application)
Number of subjects: 51
Study 30715489 — intervention group
Group type: COMPARATOR
Intervention: Active control condition (walking with a pedometer and exercise only)
Number of subjects: 51
Study 28056569 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnesium sulfate (MgSO4)
Number of subjects: 2241
Study 28056569 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2241
Study 27438687 — intervention group
Group type: EXPERIMENTAL
Intervention: Aripiprazole augmentation
Number of subjects: 159
Study 27438687 — intervention group
Group type: EXPERIMENTAL
Intervention: Base combined moderator (Mb*)
Number of subjects: 159
Study 27438687 — intervention group
Group type: EXPERIMENTAL
Intervention: Full combined moderator (Mf*)
Number of subjects: 159
Study 27438687 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus continuation venlafaxine monotherapy
Number of subjects: 159
Study 25350473 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydromorphone extended release (ER)
Number of subjects: 267
Study 25350473 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 267
Study 21843020 — intervention group
Group type: EXPERIMENTAL
Intervention: Participants who experienced success with a 24-hr rest interval
Number of subjects: 4
Study 21843020 — intervention group
Group type: COMPARATOR
Intervention: Participants who did not feel successful or had a 5-min rest interval
Number of subjects: 4
Study 19240707 — intervention group
Group type: EXPERIMENTAL
Intervention: Visilizumab (HuM291) 10 microg/kg intravenously on 2 consecutive days
Number of subjects: 34
Study 19240707 — intervention group
Group type: EXPERIMENTAL
Intervention: Visilizumab (HuM291)
Number of subjects: 34
Study 17974123 — intervention group
Group type: EXPERIMENTAL
Intervention: Instillation of 5-aminolevulinic acid or hexyl aminolevulinate
Number of subjects: 0
Study 15090103 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer method for PTO elicitation
Number of subjects: 95
Study 15090103 — intervention group
Group type: COMPARATOR
Intervention: Face-to-face interview method for PTO elicitation
Number of subjects: 95
Study 11417612 — intervention group
Group type: EXPERIMENTAL
Intervention: Albendazole therapy
Number of subjects: 63
Study 11417612 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 63
Study 10023217 — intervention group
Group type: EXPERIMENTAL
Intervention: Laser-welded titanium frameworks
Number of subjects: 58
Study 10023217 — intervention group
Group type: COMPARATOR
Intervention: Conventional cast frameworks
Number of subjects: 58
Study 10023217 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 58